Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group…

NCT00220415 · UCB Pharma, Industry · Completed

Key facts

NCT number NCT00220415
Title A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Official title A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Lead sponsor UCB Pharma, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Partial Seizures With or Without Secondary Generalization
Intervention type Drug
Interventions SPM 927
Start date May 1, 2004
Primary completion Jan 1, 2006
Completion Jan 1, 2006
First posted Sep 22, 2005
Last update posted Sep 22, 2014
Countries Germany

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies